Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes:: improvements of the induced coagulopathy with fibrinogen concentrate

被引:128
作者
Fenger-Eriksen, C
Anker-Moller, E
Heslop, J
Ingerslev, J [1 ]
Sorensen, B
机构
[1] Aarhus Univ Hosp, Dept Clin Biochem, Ctr Haemophilia & Thrombosis, Skejby, Denmark
[2] Aarhus Univ Hosp, Dept Anaesthesiol, Aarhus Sygehus, Denmark
关键词
blood; coagulation; haemodilution; replacement; measurement techniques; thrombelastograph;
D O I
10.1093/bja/aei052
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. Plasma substitutes such as hydroxyethyl starch (HES) and various dextrans may compromise the haemostatic system, thereby causing potentially dangerous bleeding. Whilst several mechanisms have been advanced to explain the nature of the coagulopathy induced by this colloid, there has been comparably little interest in devising ways to optimize haemostasis after a relative colloid overdose. Methods. Real-time whole blood (WB) clot formation profiles were recorded using a thrombelastographic method employing activation with tissue factor. The coagulation tracings were transformed into dynamic velocity profiles of WB clot formation. WB from healthy individuals (n=20) was exposed to haemodilution of similar to55% with isotonic saline, HES 200/0.5, HES 130/0.4, and dextran 70, respectively. Possible modalities for improvement of the induced coagulopathy were explored, in particular ex vivo addition of a fibrinogen concentrate. Results. WB coagulation profiles changed significantly with decreased clot strength, and a compromised propagation phase of clot formation. The duration of the initiation phase of WB coagulation was unchanged. No statistical differences were detected amongst the HES solutions and dextran 70. However, dextran 70 returned a more suppressed clot development and strength compared with the HES solutions. Ex vivo haemostatic addition of washed platelets (75 x10(9) litre(-1)) and factor VIII (0.6 IU ml(-1)) produced insignificant changes in clot initiation, propagation, and in the clot strength. In contrast, ex vivo addition of a fibrinogen concentrate (1 g litre(-1)) improved the coagulopathy induced by all of the three individual plasma expanders tested. Conclusion. Coagulopathy induced by haemodilution with either HES 200/0.5, HES 130/0.4, and dextran 70 may be improved by fibrinogen supplementation.
引用
收藏
页码:324 / 329
页数:6
相关论文
共 20 条
  • [1] DAMON L, 1987, NEW ENGL J MED, V317, P964
  • [2] Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects
    de Jonge, E
    Levi, M
    Büller, HR
    Berends, F
    Kesecioglu, J
    [J]. INTENSIVE CARE MEDICINE, 2001, 27 (11) : 1825 - 1829
  • [3] Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation
    Egli, GA
    Zollinger, A
    Seifert, B
    Popovic, D
    Pasch, T
    Spahn, DR
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1997, 78 (06) : 684 - 689
  • [4] Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight
    Entholzner, EK
    Mielke, LL
    Calatzis, AN
    Feyh, J
    Hipp, R
    Hargasser, SR
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2000, 44 (09) : 1116 - 1121
  • [5] Hemker HC, 2000, THROMB HAEMOSTASIS, V83, P589
  • [6] Compromised blood coagulation:: An in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thromboelastography
    Jamnicki, M
    Zollinger, A
    Seifert, B
    Popovic, D
    Pasch, T
    Spahn, DR
    [J]. ANESTHESIA AND ANALGESIA, 1998, 87 (05) : 989 - 993
  • [7] Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch
    Jonville-Béra, A
    Autret-Leca, E
    Gruel, Y
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (08) : 622 - 623
  • [8] Voluven®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5
    Langeron, O
    Doelberg, M
    Ang, ET
    Bonnet, F
    Capdevila, X
    Coriat, P
    [J]. ANESTHESIA AND ANALGESIA, 2001, 92 (04) : 855 - 862
  • [9] A SEVERE COAGULOPATHY FOLLOWING VOLUME REPLACEMENT WITH HYDROXYETHYL STARCH IN A JEHOVAHS WITNESS
    LOCKWOOD, DNJ
    BULLEN, C
    MACHIN, SJ
    [J]. ANAESTHESIA, 1988, 43 (05) : 391 - 393
  • [10] In vitro evaluation of the effect of profound haemodilution with hydroxyethyl starch 6%, modified fluid gelatin 4% and dextran 40 10% on coagulation profile measured by thromboelastography
    Mortier, E
    Ongenae, M
    DeBaerdemaeker, L
    Herregods, L
    DenBlauwen, N
    VanAken, J
    Rolly, G
    [J]. ANAESTHESIA, 1997, 52 (11) : 1061 - 1064